FAQ: Nutriband's AVERSA Fentanyl Abuse-Deterrent Patch and Market Outlook
Summary
Nutriband Inc. is developing AVERSA Fentanyl, an abuse-deterrent transdermal patch that releases aversive agents if tampered with, with potential annual sales reaching $200-800 million and an Outperform rating from Noble Capital Markets.
What is Nutriband Inc. and what is their main focus?
Nutriband Inc. (NASDAQ: NTRB) is a pharmaceutical company primarily engaged in developing transdermal pharmaceutical products, with their lead product being an abuse-deterrent fentanyl patch.
What is AVERSA Fentanyl and how does it work?
AVERSA Fentanyl is an abuse-deterrent transdermal patch that releases aversive agents if tampered with, reducing the risk of opioid misuse and abuse.
What are the market projections for AVERSA Fentanyl?
Market projections estimate annual sales of $200 million, potentially rising to $800 million if the FDA mandates abuse-deterrent patches across the entire category.
What is the current development timeline for AVERSA Fentanyl?
Nutriband expects to begin a human abuse liability study in early 2026 and file a New Drug Application later that year, following completion of manufacturing scale-up with Kindeva Drug Delivery.
What is Noble Capital Markets’ assessment of Nutriband?
Noble Capital Markets reaffirmed its Outperform rating and $15 price target, citing Nutriband’s ability to fund R&D through its contract manufacturing division without shareholder dilution.
What is AVERSA technology and what makes it significant?
AVERSA technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, making it a versatile abuse-deterrent solution.
Where can investors find more information about Nutriband?
The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB, and the full Channelchek report can be viewed at https://ibn.fm/bClpc.
How is Nutriband funding its research and development?
According to Noble Capital Markets, Nutriband is able to fund R&D through its contract manufacturing division without requiring shareholder dilution.
What was the context for the featured Channelchek report?
The report summarized Nutriband’s presentation at Noble’s Virtual Emerging Growth Conference and was published on October 23, 2025.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 264010